Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Miyuki, Ozawa"'
Autor:
Daiya Kase, Kenta Niitsuma, Shunsuke Hayakawa, Shota Michii, Yusuke Sakai, Kyohei Ueyama, Masaaki Sakuma, Ryosuke Haraguchi, Daiki Sawaguchi, Miyuki Ozawa, Kentaro Sakamaki
Publikováno v:
Asian Journal of Organic Chemistry. 10:901-905
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23d6f7982c56d39acc13045644cc218e
https://doi.org/10.1002/ajoc.202100033
https://doi.org/10.1002/ajoc.202100033
Autor:
Tatiana Michelon, Cristiane Sandri, Regina Schroeder, Márcia Graudenz, Elizete Keitel, Valter Garcia, Miyuki Ozawa, Paul Terasaki, Jorge Neumann
Publikováno v:
Brazilian Journal of Transplantation, Vol 11, Iss 1 (2008)
Introdução: Anticorpos anti-HLA pré-formados ou desenvolvidos após o transplante estão associados à menor sobrevida do enxerto. A importância de anticorpos contra aloantígenos MICA ainda não é clara. Objetivo: Determinar a prevalência de a
Externí odkaz:
https://doaj.org/article/3e56ee9fbb834edda41144c67402808a
Autor:
Nori Sasaki, Lorita M. Rebellato, Scott A. Kendrick, Paul Bolin, Carl E. Haisch, Maria Cecilia S. Freitas, K. Parker, Miyuki Ozawa, Anh Nguyen, Matthew J Everly, Paul I. Terasaki, Robert C. Harland, Kimberly P. Briley, W. Kendrick
Publikováno v:
Transplantation. 95:1113-1119
Background Anti-HLA-DQ antibodies are the predominant HLA class II donor-specific antibodies (DSAs) after transplantation. Recently, de novo DQ DSA has been associated with worse allograft outcomes. The aim of this study was to determine the further
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0beb56ca9812e355ea90cd2b5f0e0d30
https://doi.org/10.1097/tp.0b013e3182888db6
https://doi.org/10.1097/tp.0b013e3182888db6
Publikováno v:
International Immunology. 24:43-57
The non-donor-specific anti-HLA-Ia antibodies correlate significantly with lower graft survival in organ transplant patients. Based on our earlier findings that anti-HLA-E murine monoclonal antibodies (MEM-E/02 and 3D12) reacted with different HLA-Ia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc9d0645e14e08ab618177e2fef6a1e
https://doi.org/10.1093/intimm/dxr094
https://doi.org/10.1093/intimm/dxr094
Autor:
John D. Smith, Marlene L. Rose, I. M. Hamour, Miyuki Ozawa, A. Goh, Paul I. Terasaki, Derek R. Robinson, Nicholas R. Banner
Publikováno v:
American Journal of Transplantation. 11:312-319
Preformed donor HLA-specific antibodies are a known indicator for poor patient survival after cardiac transplantation. The role of de novo donor-specific antibodies (DSA) formed after cardiac transplantation is less clear. Here we have retrospectivel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2300cd0a214eec1a170dd2edba12a4f4
https://doi.org/10.1111/j.1600-6143.2010.03383.x
https://doi.org/10.1111/j.1600-6143.2010.03383.x
Autor:
Paul G. Catrou, Paul I. Terasaki, Kimberly P. Briley, Carl E. Haisch, Miyuki Ozawa, Matthew J Everly, Lorita M. Rebellato
Publikováno v:
Transplantation. 89:962-967
Background. The common endpoint in the treatment of antibody-mediated rejection (AMR) is functional reversal (creatinine levels). Reduction of human leukocyte antigen (HLA) antibody strength is not commonly considered as an essential endpoint for AMR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::055cb196504f59ec8fb4d78c7e8ed149
https://doi.org/10.1097/tp.0b013e3181cbac02
https://doi.org/10.1097/tp.0b013e3181cbac02
Autor:
Miyuki Ozawa, Márcia Silveira Graudenz, Tatiana Michelon, Regina Barbosa Schroeder, Cristiane Sandri, Paul I. Terasaki, Valter Duro Garcia, Elizete Keitel, Jorge Neumann
Publikováno v:
Brazilian Journal of Transplantation. 11:848-855
Introdução: Anticorpos anti-HLA pré-formados ou desenvolvidos após o transplante estão associados à menor sobrevida do enxerto. A importância de anticorpos contra aloantígenos MICA ainda não é clara. Objetivo: Determinar a prevalência de a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c3bc73984bdfc78933217b1d3d7d16c
https://doi.org/10.53855/bjt.v11i1.280
https://doi.org/10.53855/bjt.v11i1.280
Autor:
Anne Rosen, Paul I. Terasaki, Joshua Miller, Kazuo Mizutani, Miyuki Ozawa, E. Hamdani, Violet Esquenazi
Publikováno v:
American Journal of Transplantation. 7:1027-1031
Approximately 25% of patients who undergo kidney transplantation develop HLA-specific antibodies, the strength of which has not been previously correlated with graft failure. The strength of these de novo antibodies is investigated in this study. Ser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8213c169654a3327177ad4e4bb9f3c8c
https://doi.org/10.1111/j.1600-6143.2006.01721.x
https://doi.org/10.1111/j.1600-6143.2006.01721.x
Publikováno v:
American Journal of Transplantation. 7:408-415
In 2002, 1329 patients with functioning transplants were prospectively tested for HLA antibodies in the 13th International Histocompatibility Workshop. Four years after testing, deceased donor graft survival among 806 patients not having antibodies i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7cc1a29a974b527d7bb2f8615b303fe
https://doi.org/10.1111/j.1600-6143.2006.01644.x
https://doi.org/10.1111/j.1600-6143.2006.01644.x
Autor:
Paul I. Terasaki, Miyuki Ozawa
Publikováno v:
Transplantation. 80:1194-1197
In this large collaborative study, 2,231 transplanted patients with functioning kidneys were tested for HLA antibodies, then examined 2 years later for graft survival. Among 478 patients with antibodies, 15.1% failed in 2 years, compared to 6.8% fail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27e7f90dea384d0273417eaac879fca2
https://doi.org/10.1097/01.tp.0000174338.97313.5a
https://doi.org/10.1097/01.tp.0000174338.97313.5a